Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"

From Libre Pathology
Jump to navigation Jump to search
 
(10 intermediate revisions by the same user not shown)
Line 3: Line 3:
==General==
==General==
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal  | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue =  | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref>
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal  | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue =  | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref>
*May represent ''or'' overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}}
*The main differential diagnosis is ''metastatic adenocarcinoma''.


==IHC==
==IHC==
Features:<ref name=pmid28555282/>
Features:<ref name=pmid28555282/>
*CK7 +ve.
*CK7 +ve.
*TTF-1 -ve.
*[[TTF-1]] -ve.
*HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/>
*HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/>
*SMARCA4 -ve.
*SMARCA4 -ve.
*Napsin A -ve (1/28 +ve).<ref>{{cite journal |authors=Sayeda S, Naqvi A, Begum H, Finley C, Coschi C, Juergens R, Bonert M. |title=34th European Congress of Pathology - Abstracts (''Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status'') |journal=Virchows Arch |volume=481 |issue=Suppl 1 |pages=1–364 |date=August 2022 |pmid=35972647 |pmc=9379246 |doi=10.1007/s00428-022-03379-4 |url=}}</ref>
Note:
*Hepatoid [[adenocarcinoma of lung]] shows cytoplasmic [[TTF-1]] staining.<ref name=pmid24030743>{{Cite journal  | last1 = Haninger | first1 = DM. | last2 = Kloecker | first2 = GH. | last3 = Bousamra Ii | first3 = M. | last4 = Nowacki | first4 = MR. | last5 = Slone | first5 = SP. | title = Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. | journal = Mod Pathol | volume = 27 | issue = 4 | pages = 535-42 | month = Apr | year = 2014 | doi = 10.1038/modpathol.2013.170 | PMID = 24030743 }}</ref>
==Sign out==
<pre>
The tumour stains as follows:
POSITIVE: CK7 (diffuse, strong), HepPar-1 (strong, diffuse).
NEGATIVE: TTF-1, napsin A, p63, CK5/6.
The staining pattern for this tumour is not typical for lung adenocarcinoma; please correlate with the clinical findings.
HepPar-1 POSITIVITY with CK7 POSITIVITY and TTF-1 NEGATIVITY may be seen in SMARCA4-deficient adenocarcinoma of the lung.[1]
1. Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
</pre>


==See also==
==See also==
*[[Lung adenocarcinoma]].
*[[Lung adenocarcinoma]].
*[[SMARCB1]] (INI-1).


==References==
==References==

Latest revision as of 15:57, 31 October 2023

SMARCA4-deficient non-small cell carcinoma of the lung is an emerging subtype of lung cancer.[1]

General

  • ~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.[2]
  • May represent or overlap with what is known as hepatoid adenocarcinoma of the lung.[citation needed]
  • The main differential diagnosis is metastatic adenocarcinoma.

IHC

Features:[1]

  • CK7 +ve.
  • TTF-1 -ve.
  • HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).[1]
  • SMARCA4 -ve.
  • Napsin A -ve (1/28 +ve).[3]

Note:

Sign out

The tumour stains as follows: 
POSITIVE: CK7 (diffuse, strong), HepPar-1 (strong, diffuse).
NEGATIVE: TTF-1, napsin A, p63, CK5/6.

The staining pattern for this tumour is not typical for lung adenocarcinoma; please correlate with the clinical findings.

HepPar-1 POSITIVITY with CK7 POSITIVITY and TTF-1 NEGATIVITY may be seen in SMARCA4-deficient adenocarcinoma of the lung.[1]

1. Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.

See also

References

  1. ↑ 1.0 1.1 1.2 Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
  2. ↑ Herpel, E.; Rieker, RJ.; Dienemann, H.; Muley, T.; Meister, M.; Hartmann, A.; Warth, A.; Agaimy, A. (Feb 2017). "SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.". Ann Diagn Pathol 26: 47-51. doi:10.1016/j.anndiagpath.2016.10.006. PMID 28038711.
  3. ↑ Sayeda S, Naqvi A, Begum H, Finley C, Coschi C, Juergens R, Bonert M. (August 2022). "34th European Congress of Pathology - Abstracts (Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status)". Virchows Arch 481 (Suppl 1): 1–364. doi:10.1007/s00428-022-03379-4. PMC 9379246. PMID 35972647. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379246/.
  4. ↑ Haninger, DM.; Kloecker, GH.; Bousamra Ii, M.; Nowacki, MR.; Slone, SP. (Apr 2014). "Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature.". Mod Pathol 27 (4): 535-42. doi:10.1038/modpathol.2013.170. PMID 24030743.
Retrieved from "https://librepathology.org/w/index.php?title=SMARCA4-deficient_non-small_cell_carcinoma_of_the_lung&oldid=52472"